Results 21 to 30 of about 70,073 (274)

Epiregulin expression and secretion is increased in castration-resistant prostate cancer

Frontiers in Oncology, 2023
IntroductionIn prostate cancer, long-term treatment directed against androgens often leads to the development of metastatic castration-resistant prostate cancer, which is more aggressive and not curatively treatable.
Marc Wiesehöfer, Benedikt Bernhard Gereon Raczinski, Caroline Wiesehöfer, Jaroslaw Thomas Dankert, Elena Dilara Czyrnik, Martin Spahn, Martin Spahn, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Marianna Kruithof-de Julio, Gunther Wennemuth   +11 more
doaj   +1 more source

Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.

European Journal of Cancer, 2023
BACKGROUND Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant to making management decisions in
S. Gillessen, A. Bossi, I. Davis, J. D. de Bono, K. Fizazi, N. James, N. Mottet, N. Shore, E. Small, M. Smith, C. Sweeney, B. Tombal, E. Antonarakis, A. Aparicio, A. Armstrong, G. Attard, T. Beer, H. Beltran, A. Bjartell, P. Blanchard, A. Briganti, R. Bristow, M. Bulbul, O. Caffo, D. Castellano, E. Castro, Heather H. Cheng, K. Chi, S. Chowdhury, C. Clarke, N. Clarke, G. Daugaard, M. De Santis, I. Durán, R. Eeles, E. Efstathiou, J. Efstathiou, O. Ekeke, C. P. Evans, S. Fanti, F. Feng, V. Fonteyne, N. Fossati, M. Frydenberg, Daniel J. George, M. Gleave, G. Gravis, S. Halabi, D. Heinrich, K. Herrmann, C. Higano, M. Hofman, L. Horvath, M. Hussain, B. Jereczek-Fossa, Rob J Jones, R. Kanesvaran, P. Kellokumpu-Lehtinen, R. Khauli, L. Klotz, G. Kramer, R. Leibowitz, C. Logothetis, B. Mahal, F. Maluf, J. Mateo, D. Matheson, N. Mehra, A. Merseburger, A. Morgans, M. Morris, H. Mrabti, D. Mukherji, D. Murphy, V. Murthy, P. Nguyen, W. Oh, P. Ost, J. O’Sullivan, A. Padhani, C. Pezaro, D. Poon, C. Pritchard, D. Rabah, D. Rathkopf, R. Reiter, M. Rubin, C. Ryan, F. Saad, J. P. Sade, O. Sartor, H. Scher, N. Sharifi, I. Skoneczna, H. Soule, D. Spratt, S. Srinivas, C. Sternberg, T. Steuber, Hiroyoshi Suzuki, M. Sydes, M. Taplin, D. Tilki, L. Türkeri, F. Turco, Hiroji Uemura, H. Uemura, Y. Ürün, C. Vale, I. V. van Oort, N. Vapiwala, J. Walz, K. Yamoah, Dingwei Ye, E. Yu, A. Zapatero, T. Zilli, A. Omlin   +117 more
semanticscholar   +1 more source

Guidelines for Evaluating Treatment Response Based on Bone Scan for Metastatic Castration-Resistant Prostate Cancer: Prostate Cancer Clinical Trial Working Group 3 Recommendations

Journal of the Korean Society of Radiology, 2023
In prostate cancer, the bone is the most common site of metastasis, and it is essential to evaluate metastatic bone lesions to assess the tumor burden and treatment response.
Ji Sung Jang, Amy Junghyun Lee, Kye Jin Park, Kyung Won Kim, Hyo Jung Park   +4 more
doaj   +1 more source

Utility of plasma cell‐free DNA in metastatic castration‐resistant prostate cancer

IJU Case Reports, 2020
Introduction Cell‐free DNA is suggested as a prognostic biomarker in metastatic castration‐resistant prostate cancer. However, it remains unknown which parameter of cell‐free DNA is correlated with the progression and prognosis of metastatic castration ...
Itsuto Hamano, Shingo Hatakeyama, Tomoko Hamaya, Kyo Togashi, Teppei Okamoto, Hayato Yamamoto, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara Ohyama   +9 more
doaj   +1 more source

Novel Strategies for Treating Castration-Resistant Prostate Cancer

Biomedicines, 2021
The development of castration resistance is an inevitable pathway for the vast majority of patients with advanced prostate cancer. Recently, there have been significant breakthroughs in the understanding and management options of castration-resistant ...
David Ka-Wai Leung, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh   +3 more
doaj   +1 more source

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

The Lancet Oncology, 2022
BACKGROUND Metastatic castration-resistant prostate cancers are enriched for DNA repair gene defects (DRDs) that can be susceptible to synthetic lethality through inhibition of PARP proteins.
M. Smith, H. Scher, S. Sandhu, E. Efstathiou, P. Lara, E. Yu, D. George, K. Chi, F. Saad, O. Ståhl, D. Olmos, D. Danila, G. Mason, B. Espina, Xin Zhao, K. Urtishak, P. Francis, A. Lopez-Gitlitz, K. Fizazi   +18 more
semanticscholar   +1 more source

Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments

Cancers, 2023
Simple Summary Castration-resistant prostate cancer (CRPC) remains a significant medical challenge, even with recent advancements in diagnosis and treatment.
Thi Khanh Le, Q. Duong, V. Baylot, Christelle Fargette, M. Baboudjian, Laurence Colleaux, David Taïeb, P. Rocchi   +7 more
semanticscholar   +1 more source

Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer

Scientific Reports, 2023
Prostate cancer is the most prevalent cancer in men worldwide and is promoted by the sex hormone androgen. Expression of androgen from the testis can be significantly reduced through castration.
Won Sik Shin, Seung Hyun Han, Kyung Won Jo, Yunje Cho, Kyong-Tai Kim   +4 more
doaj   +1 more source

20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. [PDF]

PLoS ONE, 2014
Castration-resistant progression of prostate cancer after androgen deprivation therapies remains the most critical challenge in the clinical management of prostate cancer.
Bo Cao, Yanfeng Qi, Yan Yang, Xichun Liu, Duo Xu, Wei Guo, Yang Zhan, Zhenggang Xiong, Allen Zhang, Alun R Wang, Xueqi Fu, Haitao Zhang, Lijing Zhao, Jingkai Gu, Yan Dong   +14 more
doaj   +1 more source

Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authors’ experience

Медицинский совет, 2021
Prostate cancer is one of the most common neoplasms in men. It currently ranks second in Russian Federation amongst male population in overall number of cases after only lung cancer and third in cancer mortality.
T. V. Ustinova, L. V. Bolotina, A. A. Paichadze, A. A. Kachmazov, A. A. Fedenko, A. D. Kaprin   +5 more
doaj   +1 more source